203 related articles for article (PubMed ID: 31170111)
1. Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.
Scordo M; Lin RJ; Sauter CS
Curr Opin Hematol; 2019 Jul; 26(4):288-293. PubMed ID: 31170111
[TBL] [Abstract][Full Text] [Related]
2. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
4. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
[TBL] [Abstract][Full Text] [Related]
5. CD19-directed CAR T-cell therapy in B-cell NHL.
Kersten MJ; Spanjaart AM; Thieblemont C
Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y; Kanemasa Y; Sasaki Y; Sei M; Matsuo T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
Cancer Med; 2023 Sep; 12(17):17808-17821. PubMed ID: 37635630
[TBL] [Abstract][Full Text] [Related]
7. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
9. Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy.
Bachanova V; Perales MA; Abramson JS
Blood Rev; 2020 Mar; 40():100640. PubMed ID: 31780119
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
11. How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Gisselbrecht C; Van Den Neste E
Br J Haematol; 2018 Sep; 182(5):633-643. PubMed ID: 29808921
[TBL] [Abstract][Full Text] [Related]
12. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
Albanyan O; Chavez J; Munoz J
Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
14. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
15. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Kanwal B
Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
17. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Davis JA; Shockley A; Glode AE
J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
[No Abstract] [Full Text] [Related]
18. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
19. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
20. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?
Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
